Raleigh, NC, 4 December 2020 – Catalyst Clinical Research has ranked number nine on the Triangle Business Journal’s (TBJ) list of fastest 50 growing companies for 2020, a designation that salutes the fastest-growing privately held companies in the Research Triangle region.
The companies named to the Fast 50 for 2020 were recognized during a virtual event hosted by the Triangle Business Journal on Thursday, December 3.
A clinical development organization providing customizable clinical research solutions to the global biopharmaceutical industry, Catalyst Clinical Research has offices in Raleigh, Durham, Wilmington, NC, Clinton, CT, as well as in the European Union.
Acknowledging the TBJ recognition, Catalyst CEO Nick Dyer said the Fast 50 ranking is another metric highlighting the company’s growth trajectory during the past year.
“We are proud to be included among the Fast 50 and appreciate this recognition by the Triangle Business Journal,” Dyer says. “This has been an important year for Catalyst in terms of growth within the Triangle and internationally. Catalyst was also recognized in August as one of the Inc.com 5000 fastest growing companies in America.
Vice President of Growth Strategy Kathy Bradrick said the company will maintain its commitment to the region. “This designation is important to our team,” said Bradrick, who is based in Raleigh. “We look forward to continuing to be an engaged, corporate citizen of the Triangle area.”
Companies eligible for the Fast 50 designation must meet several criteria, including:
- Independent and privately held
- Based and headquartered in one of the 16 counties that comprise the Triangle region: Chatham, Durham, Edgecombe, Franklin, Granville, Harnett, Johnston, Lee, Moore, Nash, Orange, Person, Vance, Wake, Warren and Wilson
- Completed three full years of operation by December 31, 2019 with revenue of at least $10 million in 2019
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry. With offices in the US and EU, the company provides global resourcing and functional solutions as well as a full-service CRO offering, the latter focused exclusively on oncology. Catalyst’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.
Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.